severe cutaneous adverse reaction

severe cutaneous adverse reaction

,

SCAR.

Any of several potentially life-threatening rashes resulting from exposure to a drug. Included in this group are acute generalized exanthematous pustulosis, drug reactions with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
References in periodicals archive ?
Discontinue CRESEMBA if a patient develops a severe cutaneous adverse reaction.
The secondary outcome was in-hospital death during that hospitalization for severe cutaneous adverse reaction.
In the crude analysis, age, comorbidity index score, and any use of diuretics were significantly associated with a severe cutaneous adverse reaction.
CHICAGO - Severe cutaneous adverse reactions requiring hospitalization occurred in 45 of 90,358 patients who began allopurinol treatment within a specified time period, for an incidence rate of 0.
The standardized incidence rate of Hospitalization for severe cutaneous adverse reactions was 0.
The hazard rate for severe cutaneous adverse reactions with allopurinol was 21.
The bulk of the severe cutaneous adverse reactions, 20 of the 45 cases, occurred within the first 30 days of treatment (incidence rate, 2.
NESINA, KAZANO, and OSENI are contraindicated in patients with a history of serious hypersensitivity reaction to any of the components of these products, such as anaphylaxis, angioedema, or severe cutaneous adverse reactions.
Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with alogliptin such as anaphylaxis, angioedema or severe cutaneous adverse reactions.
The pharmacogenomics of severe cutaneous adverse reactions to allopurinol have been recently elucidated in the Han Chinese.
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
reported on 281 patients with Stevens-Johnson syndrome (SJS) or toxic epidermal necrosis (TEN) treated in French and German hospitals under the auspices of the European Registry of Severe Cutaneous Adverse Reactions (EuroSCAR) study group.
Full browser ?